Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.51% | Add +2.7% | 415,505 | $82.93 | $34M | +11,000 | +$2M |
| STXS - Stereotaxis | 8.01% | Hold | 13,680,554 | $2.12 | $29M | — | — |
| RVMD - Revolution Medicines | 6.88% | Add +3.2% | 677,176 | $36.79 | $25M | +21,000 | +$2M |
| Blueprint Medicines | 5.97% | Add +10.8% | 168,763 | $128.18 | $22M | +16,500 | +$8M |
| Merus Bv | 5.79% | Reduce −13.6% | 398,804 | $52.60 | $21M | −63,000 | +$2M |
| ATRC - Atricure | 5.36% | Hold | 592,273 | $32.77 | $19M | — | — |
| CYTK - Cytokinetics | 3.63% | Hold | 398,100 | $33.04 | $13M | — | — |
| IDYA - Ideaya Biosciences | 3.59% | Add +5.0% | 619,090 | $21.02 | $13M | +29,760 | +$3M |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.58% | Hold | 102,500 | $126.51 | $13M | — | — |
| ASND - Ascendis Pharma A/S | 3.46% | Reduce −9.6% | 72,677 | $172.60 | $13M | −7,721 | +$13K |
| XENE - Xenon Pharmaceuticals | 2.49% | Add +5.2% | 287,939 | $31.30 | $9M | +14,200 | −$171K |
| NBIX - Neurocrine Biosciences | 2.45% | Reduce −1.4% | 70,615 | $125.69 | $9M | −1,000 | +$955K |
| AXGN - Axogen | 2.22% | Add +9.0% | 741,782 | $10.85 | $8M | +61,000 | −$5M |
| Kalvista Pharmaceuticals | 1.82% | Reduce −22.7% | 581,757 | $11.31 | $7M | −170,602 | −$2M |
| DXCM - Dexcom | 1.58% | Hold | 65,552 | $87.29 | $6M | — | — |
| DAWNGBX — | 1.58% | Add +20.2% | 879,163 | $6.50 | $6M | +147,800 | −$85K |
| STOK - Stoke Therapeutics | 1.57% | Add +13.1% | 501,972 | $11.35 | $6M | +57,974 | +$3M |
| TNDM - Tandem Diabetes Care | 1.51% | Hold | 294,208 | $18.64 | $5M | — | — |
| RCUS - Arcus Biosciences | 1.41% | Add +0.4% | 627,626 | $8.14 | $5M | +2,500 | +$202K |
| SNDX - Syndax Pharmaceuticals | 1.41% | Reduce −0.2% | 543,602 | $9.37 | $5M | −900 | −$2M |
| MLYS - Mineralys Therapeutics | 1.39% | Add +20.2% | 371,523 | $13.53 | $5M | +62,323 | +$117K |
| URGN - Urogen Pharma | 1.32% | Reduce −29.0% | 349,515 | $13.70 | $5M | −143,000 | −$659K |
| INGN - Inogen | 1.18% | Add +32.2% | 605,625 | $7.03 | $4M | +147,560 | +$992K |
| LKFT - Galapagos | 1.01% | Hold | 130,175 | $27.99 | $4M | — | — |
| BHVN - Biohaven | 0.92% | Add +6.8% | 235,235 | $14.11 | $3M | +15,000 | −$2M |
| PRQR - Proqr Therapeutics | 0.88% | Hold | 1,567,561 | $2.04 | $3M | — | — |
| EWTX - Edgewise Therapeutics | 0.86% | Add +30.0% | 238,140 | $13.11 | $3M | +55,000 | −$907K |
| PODD - Insulet | 0.86% | Reduce −16.8% | 9,900 | $314.18 | $3M | −2,000 | −$15K |
| IMVT - Immunovant | 0.85% | Add +12.6% | 191,493 | $16.00 | $3M | +21,497 | +$159K |
| ALKS - Alkermes | 0.82% | Add +10.1% | 103,748 | $28.61 | $3M | +9,548 | −$142K |
| BCAX - Bicara Therapeutics | 0.81% | Add +49.5% | 317,001 | $9.29 | $3M | +105,000 | +$183K |
| TELA - Tela Bio | 0.77% | Hold | 1,441,029 | $1.94 | $3M | — | — |
| KURA - Kura Oncology | 0.74% | Hold | 463,368 | $5.77 | $3M | — | — |
| DNLI - Denali Therapeutics | 0.65% | Add +31.7% | 168,500 | $13.99 | $2M | +40,600 | +$619K |
| CMPS - Compass Pathways | 0.63% | Add +14.1% | 811,046 | $2.80 | $2M | +100,000 | +$237K |
| ALGN - Align Technology | 0.57% | Hold | 11,000 | $189.33 | $2M | — | — |
| BCRX - Biocryst Pharmaceuticals | 0.54% | Reduce −60.9% | 218,255 | $8.96 | $2M | −340,000 | −$2M |
| CATBUSD - Astria Therapeutics | 0.48% | Add +3.2% | 324,775 | $5.36 | $2M | +10,000 | +$60K |
| Keros Therapeutics | 0.48% | Hold | 130,316 | $13.35 | $2M | — | — |
| VKTX - Viking Therapeutics | 0.47% | Hold | 64,516 | $26.50 | $2M | — | — |
| ARAY - Accuray | 0.46% | Hold | 1,222,358 | $1.37 | $2M | — | — |
| BWAY - Brainsway | 0.46% | Reduce −18.8% | 127,151 | $13.15 | $2M | −29,382 | +$190K |
| ALLO - Allogene Therapeutics | 0.43% | Hold | 1,380,118 | $1.13 | $2M | — | — |
| LXEO - Lexeo Therapeutics | 0.42% | Hold | 378,083 | $4.02 | $2M | — | — |
| FHTX - Foghorn Therapeutics | 0.39% | Reduce −1.4% | 300,452 | $4.70 | $1M | −4,300 | +$300K |
| Iteos Therapeutics | 0.39% | Reduce −34.0% | 140,847 | $9.97 | $1M | −72,500 | +$131K |
| ORIC - Oric Pharmaceuticals | 0.38% | Reduce −44.1% | 135,271 | $10.15 | $1M | −106,729 | +$23K |
| CMPX - Compass Therapeutics | 0.38% | New | 526,660 | $2.60 | $1M | +526,660 | +$1M |
| Immatics | 0.36% | Hold | 245,000 | $5.38 | $1M | — | — |
| ALEC - Alector | 0.35% | Hold | 912,928 | $1.40 | $1M | — | — |
| Mediwound | 0.34% | Hold | 64,479 | $19.37 | $1M | — | — |
| GPCR - Structure Therapeutics | 0.34% | Hold | 59,000 | $20.74 | $1M | — | — |
| BDTX — | 0.32% | Add +236.4% | 471,000 | $2.48 | $1M | +331,000 | +$951K |
| LRMR - Larimar Therapeutics | 0.30% | Hold | 371,434 | $2.89 | $1M | — | — |
| Vyne Therapeutics | 0.29% | Hold | 636,103 | $1.65 | $1M | — | — |
| Gossamer Bio | 0.29% | Reduce −6.4% | 849,921 | $1.23 | $1M | −57,933 | +$47K |
| PVLA - Palvella Therapeutics | 0.27% | Hold | 43,348 | $22.54 | $977K | — | — |
| AUTL - Autolus Therapeutics | 0.27% | Reduce −27.5% | 425,616 | $2.28 | $970K | −161,051 | +$61K |
| IPSC - Century Therapeutics | 0.26% | Hold | 1,704,232 | $0.5587 | $952K | — | — |
| NGNE - Neurogene | 0.21% | Reduce −0.8% | 51,096 | $14.95 | $764K | −404 | +$161K |
| BNTX - Biontech Se | 0.21% | Reduce −33.3% | 7,000 | $106.47 | $745K | −3,500 | −$211K |
| Polypid | 0.20% | Reduce −28.6% | 207,900 | $3.53 | $734K | −83,373 | −$55K |
| Korro Bio | 0.20% | Add +22.5% | 57,691 | $12.49 | $721K | +10,605 | −$99K |
| Compugen | 0.13% | Hold | 272,402 | $1.78 | $485K | — | — |
| AQST - Aquestive Therapeutics | 0.13% | Hold | 142,000 | $3.31 | $470K | — | — |
| BCYC - Bicycle Therapeutics | 0.12% | Reduce −20.2% | 64,492 | $6.95 | $448K | −16,307 | −$238K |
| ERAS - Erasca | 0.12% | Add +2.9% | 350,000 | $1.27 | $445K | +10,000 | −$21K |
| Adicet Bio | 0.09% | Reduce −10.0% | 540,000 | $0.6100 | $329K | −60,000 | −$124K |
| ADCT - Adc Therapeutics SA | 0.09% | Reduce −45.5% | 122,081 | $2.68 | $327K | −102,000 | +$11K |
| Sutro Biopharma | 0.09% | Hold | 437,079 | $0.7139 | $312K | — | — |
| NKTR - Nektar Therapeutics | 0.07% | New | 10,000 | $25.84 | $258K | +10,000 | +$258K |
| APRE - Aprea Therapeutics | 0.06% | Hold | 137,174 | $1.69 | $232K | — | — |
| Biomx | 0.05% | Hold | 401,136 | $0.4500 | $181K | — | — |
| PRCT - Procept Biorobotics | 0.05% | New | 3,000 | $57.60 | $173K | +3,000 | +$173K |
| IFRX - Inflarx | 0.04% | Reduce −55.6% | 200,000 | $0.7900 | $158K | −250,000 | −$301K |
Showing top 50 of 75 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| 2seventy Bio | 0.60% | Exit | 0 | $4.94 | $2M | −429,252 | −$2M |
| Regulus Therapeutics | 0.42% | Exit | 0 | $1.75 | $1M | −847,176 | −$1M |
| SPRY - Ars Pharmaceuticals | 0.34% | Exit | 0 | $12.58 | $1M | −95,290 | −$1M |
| Holding | 0.32% | Exit | 0 | $0.4515 | $1M | −2,511,374 | −$1M |
| Sage Therapeutics | 0.24% | Exit | 0 | $7.95 | $860K | −108,200 | −$860K |
| TSHA - Taysha Gene Therapies | 0.21% | Exit | 0 | $1.39 | $726K | −522,500 | −$726K |
| CRDF - Cardiff Oncology | 0.13% | Exit | 0 | $3.14 | $471K | −150,000 | −$471K |
| Nevro | 0.06% | Exit | 0 | $5.84 | $222K | −38,000 | −$222K |
| Spero Therapeutics | 0.03% | Exit | 0 | $0.7200 | $90K | −125,000 | −$90K |
| Tenaya Therapeutics | 0.01% | Exit | 0 | $0.5706 | $27K | −47,319 | −$27K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2